Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00415909 · ClinicalTrials.gov registry record · Phase 2
TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00415909: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00415909 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00415909, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Objectives: * To determine the response rate and duration of response with combination of TALL-104 cells and imatinib mesylate (IM) therapy in patients with chronic myelogenous leukemia in chronic phase, that have not achieved, or have lost, adequate response to IM. * To determine the toxicity of the combination of TALL-104 cells and IM therapy in this patient population.
Interventions
- DRUG Imatinib Mesylate (IM)
- DRUG TALL-104 cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00415909
The ClinicalTrials.gov registry entry for NCT00415909 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imatinib Mesylate (IM) is the first listed.
NCT00415909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00415909 about?
NCT00415909 is a clinical study titled "TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients". Objectives: * To determine the response rate and duration of response with combination of TALL-104 cells and imatinib mesylate (IM) therapy in patients with chronic myelogenous leukemia in chronic phase, that have not achieved, or have lost, adequate response to IM. * To determine the toxicity of t...
What is the current status of trial NCT00415909?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2006-12. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00415909?
The interventions under investigation include: Imatinib Mesylate (IM) (DRUG), TALL-104 cells (DRUG).
Who is sponsoring clinical trial NCT00415909?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.